Breast cancer cells over-expressing ErbB2 depend on its activity for proliferation, because treatment of these cells with ErbB2-specific antagonistic antibodies or kinase inhibitors blocks tumor cells in the G1 phase of the cell cycle. This evidence concerns the gene ERBB2 and breast cancer.